Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1

NCT05481879 is registered in ClinicalTrials.gov with Dyne Therapeutics as lead sponsor.

NCT NCT05481879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05481879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Lead sponsor
Dyne Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 5, 2022
Completion date
July 31, 2029
Enrollment
127 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy type 1 (dm1)